These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32056137)

  • 61. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals.
    Schutt EG; Klein DH; Mattrey RM; Riess JG
    Angew Chem Int Ed Engl; 2003 Jul; 42(28):3218-35. PubMed ID: 12876730
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Italian Society of Cardiovascular Echography (SIEC) Consensus Conference on the state of the art of contrast echocardiography.
    Ital Heart J; 2004 Apr; 5(4):309-34. PubMed ID: 15185894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantification of bound microbubbles in ultrasound molecular imaging.
    Daeichin V; Akkus Z; Skachkov I; Kooiman K; Needles A; Sluimer J; Janssen B; Daemen MJ; van der Steen AF; de Jong N; Bosch JG
    IEEE Trans Ultrason Ferroelectr Freq Control; 2015 Jun; 62(6):1190-200. PubMed ID: 26067053
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis.
    Yan F; Xu X; Chen Y; Deng Z; Liu H; Xu J; Zhou J; Tan G; Wu J; Zheng H
    Ultrasound Med Biol; 2015 Oct; 41(10):2765-73. PubMed ID: 26166460
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: in vivo studies.
    Streeter JE; Gessner R; Miles I; Dayton PA
    Mol Imaging; 2010 Apr; 9(2):87-95. PubMed ID: 20236606
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advances in molecular imaging with ultrasound.
    Gessner R; Dayton PA
    Mol Imaging; 2010 Jun; 9(3):117-27. PubMed ID: 20487678
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vascular applications of contrast-enhanced ultrasound imaging.
    Mehta KS; Lee JJ; Taha AG; Avgerinos E; Chaer RA
    J Vasc Surg; 2017 Jul; 66(1):266-274. PubMed ID: 28390769
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-Dose Molecular Ultrasound Imaging with E-Selectin-Targeted PBCA Microbubbles.
    Spivak I; Rix A; Schmitz G; Fokong S; Iranzo O; Lederle W; Kiessling F
    Mol Imaging Biol; 2016 Apr; 18(2):180-90. PubMed ID: 26391990
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
    Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
    Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
    Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
    Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Microbubble Enzyme-Linked Immunosorbent Assay for the Detection of Targeted Microbubbles in in Vitro Static Binding Assays.
    Wischhusen J; Padilla F
    Ultrasound Med Biol; 2017 Jul; 43(7):1506-1519. PubMed ID: 28450034
    [TBL] [Abstract][Full Text] [Related]  

  • 72. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications in progressive diabetic nephropathy.
    Leong-Poi H
    Semin Nephrol; 2012 Sep; 32(5):494-504. PubMed ID: 23062991
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular sonography with targeted microbubbles: current investigations and potential applications.
    Hwang M; Lyshchik A; Fleischer AC
    Ultrasound Q; 2010 Jun; 26(2):75-82. PubMed ID: 20498563
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ultrasonic imaging of molecular targets.
    Schmitz G
    Basic Res Cardiol; 2008 Mar; 103(2):174-81. PubMed ID: 18324373
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano- and micro-sized agents.
    McAteer MA; Choudhury RP
    Vascul Pharmacol; 2013 Jan; 58(1-2):31-8. PubMed ID: 23103786
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterization of Contrast Agent Microbubbles for Ultrasound Imaging and Therapy Research.
    Mulvana H; Browning RJ; Luan Y; de Jong N; Tang MX; Eckersley RJ; Stride E
    IEEE Trans Ultrason Ferroelectr Freq Control; 2017 Jan; 64(1):232-251. PubMed ID: 27810805
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ultrasound molecular imaging of tumor angiogenesis with a neuropilin-1-targeted microbubble.
    Zhang H; Tam S; Ingham ES; Mahakian LM; Lai CY; Tumbale SK; Teesalu T; Hubbard NE; Borowsky AD; Ferrara KW
    Biomaterials; 2015 Jul; 56():104-13. PubMed ID: 25934284
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 80. VEGFR2-targeted molecular imaging in the mouse embryo: an alternative to the tumor model.
    Denbeigh JM; Nixon BA; Hudson JM; Puri MC; Foster FS
    Ultrasound Med Biol; 2014 Feb; 40(2):389-99. PubMed ID: 24342913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.